Comment by hentrep

For reference, dostarlimab (JEMPERLI) is essentially GSK's answer to Merck's pembrolizumab and BMS's nivolumab. Or KEYTRUDA and OPDIVO, respectively, if you're in the USA and bombarded with pharma ads. All three are monoclonal antibodies that block PD-1 on T cells, thereby stimulating the body's immune system.